Stereotaxis Receives Regulatory Approval of e-Contact™ Module in Canada

ST. LOUIS, Dec. 05, 2017 -- Stereotaxis, Inc. (OTCQX:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announced today that it has received regulatory clearance from Health Canada for its e-Contact™ Module, which provides physicians with a simple-to-interpret indicator of catheter tip-to-tissue contact. The technology was launched in Europe in June and to date has been utilized in more than 1,300 robotic catheter ablation procedures.

The e-Contact Module is Stereotaxis’ latest innovation designed to improve patient outcomes, reduce procedure times, and advance automation. Dr. Eugene Crystal, Director of Arrhythmia Services at Sunnybrook Health Sciences Centre in Toronto, and president elect of SCRN, performed the first procedures with the e-Contact module in North America during the week of November 20.

“The latest Stereotaxis innovation adds to the Niobe^® system’s inherent advantages by providing the ability to accurately determine catheter-to-tissue contact at the point of interest,” said Dr. Crystal. “This feature has the capability to further improve robotic magnetic navigation outcomes and efficiency in complex ablation procedures like AF and VT by ensuring first-pass, complete, durable linear lesions.”

Sunnybrook has been a leader in utilizing Stereotaxis technology for a broad range of arrhythmias, becoming Toronto’s first robotic arrhythmia lab with installation of the Niobe magnetic navigation system in 2010. Sunnybrook performs an estimated 70 percent of its arrhythmia ablation cases with Stereotaxis robotic technology.

About Stereotaxis
Stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Over 100 issued patents support the Stereotaxis platform. The core components of Stereotaxis’ systems have received regulatory clearance in the United States, European Union, Japan, Canada, China, and elsewhere. For more information, please visit www.stereotaxis.com.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to raise additional capital on a timely basis and on terms that are acceptable, its ability to continue to manage expenses and cash burn rate at sustainable levels, its ability to continue to work with lenders to extend, repay or refinance indebtedness, or to obtain additional financing, in either case on acceptable terms, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its systems and the timing of such purchases, competitive factors, changes resulting from healthcare reform in the United States, including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.

Stereotaxis Contacts:
David Fischel
Chairman and Chief Executive Officer

Martin C. Stammer
Chief Financial Officer

[email protected]
314-678-6100